Drugs Acting on Various Pathophysiological Pathways in Ulcerative Colitis

Ulcerative colitis is treated with aminosalicylates (5-ASA), corticosteroids, immunomodulators such as thiopurines, and biologics and small molecules that target TNF, integrins, interleukins, or JAK signaling. The choice depends on disease severity and location.

Each class acts on a different pathophysiological pathway: aminosalicylates reduce mucosal inflammation locally, corticosteroids broadly dampen the immune response, and biologics and small molecules block specific inflammatory signals such as TNF, gut-homing integrins, or JAK kinases.

It maps each drug class to where it acts on the inflamed colon mucosa and the immune pathways involved, showing how aminosalicylates, steroids, immunomodulators, and biologics interrupt inflammation at different points.

Biologics are antibody-based drugs that block specific inflammatory targets — for example anti-TNF agents, anti-integrin agents that prevent immune cells from homing to the gut, and anti-interleukin agents. They are used for moderate-to-severe disease.

JAK inhibitors are small molecules that block Janus kinase signaling inside immune cells, reducing the production of multiple inflammatory cytokines at once. They are taken orally and used for moderate-to-severe ulcerative colitis.

Yes. The figure is fully editable in SciFig — relabel drug classes, targets, and pathways, adjust the layout, and export it in publication-ready formats for your manuscript or presentation.